Can We Model the Impact of Increased Drug Treatment Expenditure on the U.K. Drug Market?

Welcome:
Guest

Advances in Health Economics and Health Services Research

ISSN: 0731-2199
Series editor(s): Prof. Michael Grossman, Prof. Bjorn Lindgren, Prof. Robert Kaestner, Prof. Kristian Bolin

Subject Area: Health Care Management/Healthcare

Content: Series Volumes | Current Volume RSS

Options: To add Favourites and Table of Contents Alerts please take a Emerald profile

Document Information:
Title:	Can We Model the Impact of Increased Drug Treatment Expenditure on the U.K. Drug Market?
Author(s):	Christine Godfrey, Steve Parrott, Gail Eaton, Anthony Culyer, Cynthia McDougall
Volume:	16 Editor(s): Björn Lindgren, Michael Grossman ISBN: 978-0-76231-233-7 eISBN: 978-1-84950-361-7
Citation:	Christine Godfrey, Steve Parrott, Gail Eaton, Anthony Culyer, Cynthia McDougall (2005), Can We Model the Impact of Increased Drug Treatment Expenditure on the U.K. Drug Market?, in Björn Lindgren, Michael Grossman (ed.) Substance Use: Individual Behaviour, Social Interactions, Markets and Politics (Advances in Health Economics and Health Services Research, Volume 16), Emerald Group Publishing Limited, pp.257-275
DOI:	10.1016/S0731-2199(05)16012-9 (Permanent URL)
Publisher:	Emerald Group Publishing Limited
Article type:	Chapter Item
Abstract:	This chapter introduces a simulation model to estimate the social costs of problem drug misusers in England and Wales, and how policies to increase the number of drug users in treatment may impact on both social costs and government expenditure. Consequences are divided into five domains – health, crime, social care, work, and driving. Social costs are estimated to be between £12 and £12.3 billion, and the total cost of government expenditure is around £3.5 billion. Increases in the numbers in treatment, are estimated to reduce social costs across a 5-year period by between £3.0 and £4.4 billion.